Article Text

Download PDFPDF
P179 Treatment and relative survival of vulvar carcinoma in Sweden 2012–16. A population-based cohort (SweGCG study)
  1. K Hellman1,
  2. C Borgfeldt2,
  3. P Dahm-Kahler3,
  4. A Floter Rådestad4,
  5. E Hjerpe1,
  6. E Holmberg5,
  7. T Hogberg6,
  8. J Marcickiewicz7,
  9. K Stalberg8,
  10. P Rosenberg9,
  11. B Tholander10,
  12. P Kjølhede11 and
  13. E Avall-Lundqvist6
  1. 1Gynecologic Oncology, Karolinska University Hospital, Stockholm
  2. 2Gynecologic Oncology, Skane University Hospital, Lund University, Lund
  3. 3Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg
  4. 4Gynecologic Cancer, Karolinska University Hospital, Stockholm
  5. 5Regional Cancer Center Western Sweden, Sahlgrenska University Hospital, Institute of Clinical Sciences, Gothenburg
  6. 6Department of Oncology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping
  7. 7Department of Obstetrics and Gynecology, Hallands Hospital, Halmstad
  8. 8Department of Obstetrics and Gynecology, Uppsala University, Uppsala
  9. 9Department of Clinical Oncology and Department of Clinical and Experimental Medicine, Linkoping University, Linkoping
  10. 10Department of Gynecologic Oncology, Uppsala University, Uppsala
  11. 11Children and Women's Health, Department of Clinical and Experimental Medicine Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden


Introduction / Background Vulvar cancer is a rare disease where treatment guidelines are mostly based on results from retrospective studies with small, heterogeneous materials. There are no data published from the Swedish population.

Methodology A population-based nationwide study on all women treated for vulvar carcinoma included in the Swedish Quality Registry for Gynecologic Cancer (SQRGC) between 2012–2016. Relative survival (RS) was estimated using the Ederer II method. Simple and multivariable analyses were estimated by Poisson regression models.

Results 657 women with squamous cell carcinoma were included in the study. The distribution by FIGO stage for stage IA, IB, II, III, IVA and IVB were18%, 37%, 12%, 19%, 5% and 3% respectively. The distribution by age at diagnosis for age groups 20–59, 60–69, 70–79 and 80–100 years were 20%, 20%, 27%, 33% respectively. 528 patients (80%) had primary surgery, 377 (57%) had surgery alone, 149 (23%) had adjuvant treatment (7% chemoradiation and 16% radiotherapy alone) and 110 (17%) received primary (chemo)radiation (6% chemoradiation and 11% radiotherapy alone). In 84% the treatment intention was curative, but only in 63% in the oldest age group (80–100). The overall 5-year RS was 75% and by stage (I, II, III and IV) it was 90%, 73%, 66% and 50% respectively. The 5-year RS per age groups (20–59, 60–69, 70–79 and 80–100 years) was 90%, 88%, 81% and 61% respectively. In the multivariate analysis there was a significant negative correlation between RS and FIGO stage (p<0.001). The oldest age group (80–100) had worse RS compared to younger age groups (<0.001) in stage I-III.

Conclusion This is the first nation-wide populationbased study reporting on treatment patterns and relative survival in vulvar carcinoma in Sweden with data from SQRGC. The elderly patients more frequently received treatment with palliative intention and had significantly worse relative survival compared to younger patients.

Disclosure Nothing to disclose.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.